IP Library Granted Patent US 10,494,431
Granted Patent B2
US 10,494,431 · App. 15/911,571 · Granted Dec 3, 2019

Cross-linkers and their uses

Inventors: Ravi V. J. Chari (Newton, MA); Robert Yongxin Zhao (Lexington, MA); Yelena Kovtun (Stow, MA); Rajeeva Singh (Framingham, MA); Wayne C. Widdison (Belmont, MA)
Assignee: IMMUNOGEN, INC.
C07K16/28A61K31/5365A61K47/65A61K47/6809A61K47/6849C07D207/46C07K5/0202C07K5/06026C07K5/0806C07K5/0819Y02A50/423Y02A50/491
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,494,431
App. No.
15/911,571
Granted
Dec 3, 2019
Kind
B2
Abstract

Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.

Claims (16)

1. A compound of formula (IV):

wherein:

Y′ represents a functional group that enables reaction with a cell-binding agent;

D represents a cytotoxic drug linked to the cell-binding agent by a disulfide, thioether, thioester, peptide, hydrazone, ester, ether, carbamate, or amide bond;

one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is a charged substituent selected from SO 3 − , X—SO 3 , OPO 3 2− , X—OPO 3 2− , N + R 11 R 12 R 13 and X—N + R 11 R 12 R 13 , and the rest are H;

R 11 , R 12 , and R 13 are the same or different and are linear alkyl having from 1 to 6 carbon atoms, or branched or cyclic alkyl having from 3 to 6 carbon atoms and X represents phenyl or a linear alkyl having from 1 to 6 carbon atoms, or branched or cyclic alkyl having from 3 to 6 carbon atoms;

l and m are each 0;

n is 1; and

Z is absent; or a polyethyleneoxy unit of formula (OCH 2 CH 2 ) p , wherein p is an integer from 2 to about 1000.

2. The compound of claim 1 , wherein the cytotoxic drug is a maytansinoid.

3. The compound of claim 2 , wherein the cytotoxic drug is DM1 or DM4.

4. The compound of claim 2 , wherein the cytotoxic drug is DM4.

5. The compound of claim 4 , wherein Y′ is an amine reactive functional group selected from the group consisting of N-hydroxysuccinmide ester, p-nitrophenyl ester, dinitrophenyl ester, and pentafluorophenyl ester.

6. The compound of claim 5 , wherein R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is SO 3 − or X—SO 3 − , and the rest are H; and Y′ is a maleimido or a N-hydroxysuccinimide ester.

7. The compound of claim 6 , wherein Y′ is N-hydroxysuccinimide ester.

8. The compound of claim 1 , wherein the compound is represented by the following formula:

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2018
From: CHARI, RAVI V.J.; ZHAO, ROBERT YONGXIN; KOVTUN, YELENA; SINGH, RAJEEVA; WIDDISON, WAYNE CHARLES
To: IMMUNOGEN, INC.
Reel/Frame 045665/0222 →
Continuity (8)
Continuation 15293579 · Oct 14, 2016
Continuation 14713419 · May 15, 2015
Continuation 14080377 · Nov 14, 2013
Continuation 13542126 · Jul 5, 2012
Division 12433604 · Apr 30, 2009
Provisional Application 61147966 · Jan 28, 2009
Provisional Application 61049291 · Apr 30, 2008
Related Publication 20180291100A1 · Oct 11, 2018